Literature DB >> 24164300

Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer.

Hanbyoul Cho1, You Sun Lee, Julie Kim, Joon-Yong Chung, Jae-Hoon Kim.   

Abstract

Illumina microarray was used to identify differentially expressed genes in three epithelial ovarian cancer (EOC) cells. To validate the microarray data, mRNA and protein level of glucose transporter-1 (GLUT-1) was examined. GLUT-1 had an EOC/normal cells ratio of 5.51 based on microarray. Real-time PCR and immunohistochemistry demonstrated that GLUT-1 expression was significantly increased in EOC (p = .029 and p < .001, respectively). On survival analysis, GLUT-1 overexpression (HR = 4.80, p = .027) and lymph node metastases (HR = 8.35, p = .016) conferred a significantly worse overall survival. In conclusion, GLUT-1 expression is remarkably upregulated in EOC and predicts a poor overall survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24164300     DOI: 10.3109/07357907.2013.849722

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  33 in total

1.  The prognostic value of GLUT-1 staining in the detection of malignant transformation in oral mucosa.

Authors:  Roman C Brands; Olga Köhler; Stephan Rauthe; Stefan Hartmann; Harald Ebhardt; Axel Seher; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2016-09-08       Impact factor: 3.573

2.  Evaluation of a hypoxia regulated gene panel in ovarian cancer.

Authors:  Amanda F Baker; Scott W Malm; Ritu Pandey; Cindy Laughren; Haiyan Cui; Denise Roe; Setsuko K Chambers
Journal:  Cancer Microenviron       Date:  2015-05-22

Review 3.  The Warburg effect: evolving interpretations of an established concept.

Authors:  Xiaozhuo Chen; Yanrong Qian; Shiyong Wu
Journal:  Free Radic Biol Med       Date:  2014-09-30       Impact factor: 7.376

4.  Antitumor effects of WNT2B silencing in GLUT1 overexpressing cisplatin resistant head and neck squamous cell carcinoma.

Authors:  Sheng-Jiao Li; Xiao-Ning Yang; Han-Yu Qian
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 5.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Authors:  Kristin G Anderson; Ingunn M Stromnes; Philip D Greenberg
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

6.  Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells.

Authors:  Lichao Guo; Wen Zhang; Yanqi Xie; Xi Chen; Emma E Olmstead; Mengqiang Lian; Baochen Zhang; Yekaterina Y Zaytseva; B Mark Evers; H Peter Spielmann; Xifu Liu; David S Watt; Chunming Liu
Journal:  Mol Cancer Ther       Date:  2022-05-04       Impact factor: 6.009

Review 7.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

8.  Expression and clinical significance of glucose transporter-1 in pancreatic cancer.

Authors:  Kai Lu; Jian Yang; DE-Chun Li; Song-Bing He; Dong-Ming Zhu; Li-Feng Zhang; X U Zhang; Xiao-Chen Chen; Bing Zhang; Jian Zhou
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

9.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

10.  TRIM66 Overexpression Promotes Glioma Progression and Regulates Glucose Uptake Through cMyc/GLUT3 Signaling.

Authors:  Yuequn Song; Lifang Meng; Jian Yu; Zhi Cao; Jizhou Sun; Hongyu Zhao
Journal:  Cancer Manag Res       Date:  2021-06-30       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.